Confused between eczema and psoriasis? Experts explain how these skin conditions differ in symptoms, causes, and treatment.

Psoriasis is a long-term skin condition that affects millions of people around the world. It causes red, dry, and scaly ...

Organon recently presented post-hoc pooled Phase 3 ADORING 1 and 2 data showing VTAMA cream achieved early, statistically significant improvements in atopic dermatitis severity and itch versus vehicle ...

A TYK2 inhibitor in development shows superior efficacy to placebo and apremilast for treating psoriasis, with no new safety ...

Presentations at the 2026 meeting of the American Academy of Dermatology not only demonstrate the therapeutic potential of ...

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...

Alumis Inc. ALMS shares tumbled Monday despite strong clinical trial outcomes, as investors locked in gains following a 239% ...

Even though having an itch is innocuous, the underlying reason you have the itch in the first place could be more disgusting ...

Mar 28, 2026-- Takeda ( TSE:4502/NYSE:TAK ) today announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279 ...

Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI ...

Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the ...

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present results from a post-hoc sub-analysis of pooled data ...